论文部分内容阅读
[目的]探讨E-cadherin基因突变在人非小细胞肺癌(NSCLC)中的作用。[方法]采用PCR-SSCP方法检测53例非小细胞肺癌原发灶组织和5例肺部其他良恶性病变组织的E-cadherin基因突变的情况。[结果]3例NSCLC发生E-cadherin基因的突变。E-cadherin基因的突变与NSCLC的淋巴结转移情况有关(P<0.05),但与肿瘤的病理类型、原发灶情况以及预后无关(P>0.05),而且在NSCLC与肺部其他病变之间,E-cadherin基因的突变也无显著性差异。[结论]E-cadherin基因能够较好地预测非小细胞肺癌的淋巴结转移情况。
[Objective] To investigate the role of E-cadherin gene mutations in human non-small cell lung cancer (NSCLC). [Method] PCR-SSCP was used to detect the mutation of E-cadherin gene in 53 cases of primary non-small cell lung cancer tissue and 5 cases of other lung benign and malignant lesions. [Results] The mutation of E-cadherin gene was found in 3 NSCLC cases. The mutation of E-cadherin gene was associated with the lymph node metastasis of NSCLC (P <0.05), but not with the pathological type, primary tumor and prognosis (P> 0.05), but also between NSCLC and other lung lesions, E-cadherin gene mutation also no significant difference. [Conclusion] The E-cadherin gene can better predict the lymph node metastasis in non-small cell lung cancer.